Goldman Sachs Starts Talecris Biotherapeutics (TLCR) at Neutral
More News related to TLCR
- Talecris to Invest $268.7 Million to Expand its Manufacturing Facility in Clayton
- Barclays Initiates Coverage on Talecris Biotherapeutics (TLCR) with an Equalweight
- Notable Analyst Rating Changes 11/10: ADBE, ANN, FRPT, RAX Upgraded; ALU, CPST, PIKE, TRW Downgraded
- Morning Movers 11/10: UPG, CYD, PCLN, FLL, BZH Higher; RHIE, OPXT, PRKR, PIKE, MBI, SDTH Lower
- Several Brokerage Firms Initiate Coverage on Talecris Biotherapeutics (TLCR)
Goldman Sachs initiates coverage on Talecris Biotherapeutics (Nasdaq: TLCR) with a Neutral rating and a 12-month price target of $24.
The firm said the market currently values the stock at trough earnings, as TLCR is in the early stages of what we believe will be a multi-year turnaround. Over the next several quarters, they expect TLCR to accelerate gross profit growth.
Related Categories
UpgradesStocks Mentioned
-0.32Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
